- Home
- IPHA
as 03-25-2025 11:35am EST
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Upcoming Earnings Alert:
Get ready for potential market movements as Innate Pharma S.A. ADS IPHA prepares to release earnings report on 27 Mar 2025.
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 160.1M | IPO Year: | 2019 |
| Target Price: | $11.50 | AVG Volume (30 days): | 21.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.29 - $3.51 | Next Earning Date: | 03-27-2025 |
| Revenue: | $36,202,722 | Revenue Growth: | -35.38% |
| Revenue Growth (this year): | -45.91% | Revenue Growth (next year): | 93.37% |
Latest Innate Pharma S.A. ADS News
IPHA Breaking Stock News: Dive into IPHA Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
Business Wire
6 days ago
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
Business Wire
a month ago
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
MT Newswires
a month ago
Top Premarket Gainers
Pharmaceutical Technology
a month ago
Innate’s lacutamab gains FDA breakthrough therapy designation
Business Wire
a month ago
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Simply Wall St.
2 months ago
3 Promising Penny Stocks With Market Caps Under US$500M
MT Newswires
2 months ago
Sector Update: Health Care Stocks Mixed Premarket Monday
Compare IPHA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPHA Innate Pharma S.A. ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.